Bridgebio Pharma Inc (BBIO)

$77.93 +0.06 (0.08%)
Market Cap 15.10B
Revenue (ttm) 502.08M
Net Income (ttm) -724.93M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -144.39%
Debt to Equity Ratio -0.89
Volume 2,435,200
Avg Vol 2,610,310
Day's Range N/A - N/A
Shares Out 193.86M
Stochastic %K 83%
Beta 1.09
Analysts Strong Sell
Price Target $101.71

Company Profile

BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency under the NULIBRY brand name; and...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 391 9740
Address:
3160 Porter Drive, Suite 250, Palo Alto, United States
Nomorelies
Nomorelies Apr. 15 at 12:01 AM
$BBIO Nice!
0 · Reply
Nomorelies
Nomorelies Apr. 14 at 1:39 PM
$BBIO
0 · Reply
MiamiDreamin
MiamiDreamin Apr. 14 at 1:16 AM
$BBIO calls came in today might be news coming
0 · Reply
Alien1980
Alien1980 Apr. 13 at 9:38 PM
$BBIO watch for the close above 78.5 for 79.8 nice chart, similar to $MRVL that put in a new ATH .. nice intraday swing that will be on the continuation WL
0 · Reply
Alien1980
Alien1980 Apr. 13 at 7:47 PM
$BBIO Wowza! Just absolutely ripped. 75-79 👽👽
0 · Reply
theta_cat_purrs
theta_cat_purrs Apr. 13 at 7:31 PM
$BBIO 🟢 BULLISH BBIO — SWEEP: CALL $75 May 15 | Score: 65/100 | $300K IV Rank: n/a | Δ 0.00 | 31 DTE Sweep at ask · Regime: risk_on · 📊 BUY 3 CONTRACTS @ ~$6.45 · Risk: $1935 (1.0% acct) | Max loss: $1935 · Target: +50% → ~$9.67 by 2026-04-16 (3d) · Stop: -35% → cut at ~$4.19
0 · Reply
Quantumup
Quantumup Apr. 10 at 4:18 PM
BofA provided its Takeaways from their Inaugural Doctor's Day event [It's a broad research report: many Tx targets; many tickers] -- On $BBIO (Buy; $95) it said: Achondroplasia: oral is the future $ASND $BMRN $TYRA SNY PFE Here's what else BofA had to say in its note to investors: https://x.com/Quantumup1/status/2042637442155462924?s=20
0 · Reply
Nomorelies
Nomorelies Apr. 10 at 1:14 PM
$BBIO Inflation jitters. Hold!
0 · Reply
topstockalerts
topstockalerts Apr. 9 at 8:32 PM
RBC sees 35% upside ahead for BridgeBio Pharma RBC is bullish on BridgeBio Pharma , initiating coverage on the stock with an outperform rating on Wednesday. While the stock has tripled since the approval of its heart disease drug Attruby in November 2022, the firm believes it has more room to run. Its $100 price target suggests about 35% upside from Wednesday’s close. “Attruby is off to a fantastic start (annualizing ~$600M just a year post approval, and we are seeing a recent ‘second wave’ of acceleration in scripts) and our proprietary survey of 40 cardiologists clearly suggests that we are still in the early innings of uptake,” analyst Luca Issi said in a note to clients. $BBIO
0 · Reply
DonCorleone77
DonCorleone77 Apr. 9 at 6:13 PM
$BBIO Attached is a RBC Capital Markets analyst note regarding BBIO issued today.
1 · Reply
Latest News on BBIO
Acoramidis Significantly Reduces the Risk of All-Cause and Cardiovascular Mortality in Patients with ATTR-CM through Month 54

Mar 30, 2026, 3:30 PM EDT - 15 days ago

Acoramidis Significantly Reduces the Risk of All-Cause and Cardiovascular Mortality in Patients with ATTR-CM through Month 54

BridgeBio Submits NDA to FDA for BBP-418 for Individuals Living with LGMD2I/R9

Mar 30, 2026, 7:30 AM EDT - 15 days ago

BridgeBio Submits NDA to FDA for BBP-418 for Individuals Living with LGMD2I/R9

BridgeBio to Present Long-Term Efficacy and Safety Data from the ATTRibute-CM OLE Trial at the ACC Annual Scientific Sessions

Mar 23, 2026, 7:30 AM EDT - 22 days ago

BridgeBio to Present Long-Term Efficacy and Safety Data from the ATTRibute-CM OLE Trial at the ACC Annual Scientific Sessions

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Mar 20, 2026, 4:01 PM EDT - 25 days ago

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BridgeBio Pharma Eyes First Treatment For Rare Muscle Disorder As Trial Data Shows Early Progress

Mar 12, 2026, 7:47 AM EDT - 4 weeks ago

BridgeBio Pharma Eyes First Treatment For Rare Muscle Disorder As Trial Data Shows Early Progress

BBP-418 Demonstrates Consistent Efficacy and Favorable Safety Profile in Phase 3 FORTIFY Interim Analysis in LGMD2I/R9

Mar 11, 2026, 2:00 PM EDT - 4 weeks ago

BBP-418 Demonstrates Consistent Efficacy and Favorable Safety Profile in Phase 3 FORTIFY Interim Analysis in LGMD2I/R9

BridgeBio's Rare-Disease Pipeline Sparks Growth Buzz

Mar 10, 2026, 2:49 PM EDT - 5 weeks ago

BridgeBio's Rare-Disease Pipeline Sparks Growth Buzz

BridgeBio to Present Additional Data from the Phase 3 FORTIFY Trial at the 2026 MDA Clinical & Scientific Conference

Mar 4, 2026, 7:30 AM EST - 5 weeks ago

BridgeBio to Present Additional Data from the Phase 3 FORTIFY Trial at the 2026 MDA Clinical & Scientific Conference

BridgeBio Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial Updates

Feb 24, 2026, 4:01 PM EST - 7 weeks ago

BridgeBio Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial Updates

BridgeBio to Participate in March Investor Conferences

Feb 23, 2026, 7:30 AM EST - 7 weeks ago

BridgeBio to Participate in March Investor Conferences

BridgeBio to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update on February 24, 2026 at 4:30 pm ET

Feb 17, 2026, 7:30 AM EST - 2 months ago

BridgeBio to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update on February 24, 2026 at 4:30 pm ET

BridgeBio Reports Positive Phase 3 Topline Results for Oral Infigratinib with the First Statistically Significant Improvements in Body Proportionality in Achondroplasia

Feb 12, 2026, 7:30 AM EST - 2 months ago

BridgeBio Reports Positive Phase 3 Topline Results for Oral Infigratinib with the First Statistically Significant Improvements in Body Proportionality in Achondroplasia

CORRECTING and REPLACING -- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Jan 27, 2026, 5:10 PM EST - 2 months ago

CORRECTING and REPLACING -- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BridgeBio Prices Offering of $550 Million Convertible Senior Notes due 2033 to Prefund Repayment of Convertible Senior Notes due 2027

Jan 16, 2026, 1:00 AM EST - 3 months ago

BridgeBio Prices Offering of $550 Million Convertible Senior Notes due 2033 to Prefund Repayment of Convertible Senior Notes due 2027

BridgeBio Continues Long Term Debt Management Strategy and Announces Proposed Offering of Convertible Senior Notes due 2033 to Prefund Repayment of Convertible Senior Notes due 2027

Jan 14, 2026, 4:01 PM EST - 3 months ago

BridgeBio Continues Long Term Debt Management Strategy and Announces Proposed Offering of Convertible Senior Notes due 2033 to Prefund Repayment of Convertible Senior Notes due 2027

BridgeBio Announces Commercial Progress, Program Updates, and 2026 Milestones at the 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 10:30 AM EST - 3 months ago

BridgeBio Announces Commercial Progress, Program Updates, and 2026 Milestones at the 44th Annual J.P. Morgan Healthcare Conference

BridgeBio to Participate in the J.P. Morgan Healthcare Conference

Jan 5, 2026, 7:30 AM EST - 3 months ago

BridgeBio to Participate in the J.P. Morgan Healthcare Conference

BridgeBio to Host Achondroplasia Investor Webinar on Friday, January 9th at 8:00 am ET

Jan 2, 2026, 7:30 AM EST - 3 months ago

BridgeBio to Host Achondroplasia Investor Webinar on Friday, January 9th at 8:00 am ET

BridgeBio to Participate in December Investor Conferences

Nov 25, 2025, 7:30 AM EST - 5 months ago

BridgeBio to Participate in December Investor Conferences

Acoramidis Significantly Reduces All-cause Mortality in the Overall ATTR-CM Variant and V142I (V122I) Populations

Nov 8, 2025, 10:41 AM EST - 5 months ago

Acoramidis Significantly Reduces All-cause Mortality in the Overall ATTR-CM Variant and V142I (V122I) Populations

National Advertising Division Will Refer BridgeBio Pharma to Government Agencies for Failure to Participate in Inquiry

Nov 7, 2025, 1:00 PM EST - 5 months ago

National Advertising Division Will Refer BridgeBio Pharma to Government Agencies for Failure to Participate in Inquiry

BridgeBio to Participate in November Investor Conferences

Nov 4, 2025, 7:30 AM EST - 5 months ago

BridgeBio to Participate in November Investor Conferences

Biotech is back. Here's why these rallying stocks belong in your portfolio now.

Nov 3, 2025, 9:58 AM EST - 5 months ago

Biotech is back. Here's why these rallying stocks belong in your portfolio now.

ABBV ALNY AMGN BMY LLY MBX MDGL

BridgeBio to Present Data from the Overall ATTR-CM Variant and V142I (V122I) Populations from ATTRibute-CM at the AHA Scientific Sessions 2025

Nov 3, 2025, 7:30 AM EST - 5 months ago

BridgeBio to Present Data from the Overall ATTR-CM Variant and V142I (V122I) Populations from ATTRibute-CM at the AHA Scientific Sessions 2025

BridgeBio Reports Third Quarter 2025 Financial Results and Business Updates

Oct 29, 2025, 4:01 PM EDT - 5 months ago

BridgeBio Reports Third Quarter 2025 Financial Results and Business Updates

BridgeBio Reports Positive Phase 3 Topline Results for Encaleret in Patients with Autosomal Dominant Hypocalcemia Type 1

Oct 29, 2025, 7:00 AM EDT - 5 months ago

BridgeBio Reports Positive Phase 3 Topline Results for Encaleret in Patients with Autosomal Dominant Hypocalcemia Type 1

BridgeBio to Report Phase 3 Results for Encaleret in ADH1 CALIBRATE Study on Wednesday, October 29th

Oct 28, 2025, 4:01 PM EDT - 6 months ago

BridgeBio to Report Phase 3 Results for Encaleret in ADH1 CALIBRATE Study on Wednesday, October 29th

BridgeBio Reports Positive Phase 3 Results for Small Molecule BBP-418 in LGMD2I/R9 FORTIFY Study

Oct 27, 2025, 7:00 AM EDT - 6 months ago

BridgeBio Reports Positive Phase 3 Results for Small Molecule BBP-418 in LGMD2I/R9 FORTIFY Study

BridgeBio to Report Phase 3 Results for Small Molecule BBP-418 in LGMD2I/R9 FORTIFY Study, along with Third Quarter 2025 Financial Results Next Week

Oct 24, 2025, 4:01 PM EDT - 6 months ago

BridgeBio to Report Phase 3 Results for Small Molecule BBP-418 in LGMD2I/R9 FORTIFY Study, along with Third Quarter 2025 Financial Results Next Week

Acoramidis Begins to Reduce Cumulative Cardiovascular Outcomes Within the First Month of Treatment in Patients with ATTR-CM

Sep 28, 2025, 11:15 AM EDT - 7 months ago

Acoramidis Begins to Reduce Cumulative Cardiovascular Outcomes Within the First Month of Treatment in Patients with ATTR-CM

BridgeBio to Present Additional Cardiovascular Outcomes Data from ATTRibute-CM at the HFSA Annual Scientific Meeting 2025

Sep 22, 2025, 7:30 AM EDT - 7 months ago

BridgeBio to Present Additional Cardiovascular Outcomes Data from ATTRibute-CM at the HFSA Annual Scientific Meeting 2025

Encaleret Showed Parathyroid Hormone-Independent Normalization of Blood and Urine Calcium in Phase 2 Proof-of-Concept Study in Post-Surgical Hypoparathyroidism

Sep 6, 2025, 2:30 PM EDT - 7 months ago

Encaleret Showed Parathyroid Hormone-Independent Normalization of Blood and Urine Calcium in Phase 2 Proof-of-Concept Study in Post-Surgical Hypoparathyroidism

BridgeBio to Host Autosomal Dominant Hypocalcemia Type 1 (ADH1) Investor Webinar on Wednesday, September 10th at 8:00 am ET

Sep 3, 2025, 7:30 AM EDT - 7 months ago

BridgeBio to Host Autosomal Dominant Hypocalcemia Type 1 (ADH1) Investor Webinar on Wednesday, September 10th at 8:00 am ET

BridgeBio to Present Phase 2 Proof-of-Concept Data for Encaleret in Post-Surgical Hypoparathyroidism

Sep 2, 2025, 7:30 AM EDT - 8 months ago

BridgeBio to Present Phase 2 Proof-of-Concept Data for Encaleret in Post-Surgical Hypoparathyroidism

Acoramidis Demonstrates Statistically Significant Reduction in Cardiovascular Mortality (CVM) through Month 42 of the ATTRibute-CM Open Label Extension

Aug 30, 2025, 7:15 AM EDT - 8 months ago

Acoramidis Demonstrates Statistically Significant Reduction in Cardiovascular Mortality (CVM) through Month 42 of the ATTRibute-CM Open Label Extension

BridgeBio to Participate in September Investor Conferences

Aug 27, 2025, 7:30 AM EDT - 8 months ago

BridgeBio to Participate in September Investor Conferences

BridgeBio to Present Additional Open-label Extension Data from ATTRibute-CM at ESC Congress 2025

Aug 25, 2025, 7:30 AM EDT - 8 months ago

BridgeBio to Present Additional Open-label Extension Data from ATTRibute-CM at ESC Congress 2025

‘BUY THAT THING': Historically undervalued stock now has value, says wealth expert

Aug 19, 2025, 5:30 PM EDT - 8 months ago

‘BUY THAT THING': Historically undervalued stock now has value, says wealth expert

BridgeBio Reports Second Quarter 2025 Financial Results and Business Updates

Aug 5, 2025, 4:01 PM EDT - 9 months ago

BridgeBio Reports Second Quarter 2025 Financial Results and Business Updates

Biotech Has Been Stalling. 3 Stocks That Could See Healthy Gains.

Jul 30, 2025, 12:37 PM EDT - 9 months ago

Biotech Has Been Stalling. 3 Stocks That Could See Healthy Gains.

AMGN INSM

Novel Human Genetics Evidence Confirms Estimates of Genetic Prevalence, Underdiagnosis, and Potentially Greater Symptom Burden of Gain-of-Function CASR Variants Associated with ADH1

Jul 23, 2025, 7:30 AM EDT - 9 months ago

Novel Human Genetics Evidence Confirms Estimates of Genetic Prevalence, Underdiagnosis, and Potentially Greater Symptom Burden of Gain-of-Function CASR Variants Associated with ADH1

BridgeBio to Host Second Quarter 2025 Financial Results Conference Call on Tuesday, August 5, 2025 at 4:30 pm ET

Jul 22, 2025, 7:30 AM EDT - 9 months ago

BridgeBio to Host Second Quarter 2025 Financial Results Conference Call on Tuesday, August 5, 2025 at 4:30 pm ET

It is time for a move higher in biotech, says Mizuho's Jared Holz

Jul 7, 2025, 6:29 PM EDT - 10 months ago

It is time for a move higher in biotech, says Mizuho's Jared Holz

BMRN GILD INSM XBI

BridgeBio Raises $300 Million Through Partial Capped Monetization of BEYONTTRA® European Royalty

Jun 30, 2025, 7:30 AM EDT - 10 months ago

BridgeBio Raises $300 Million Through Partial Capped Monetization of BEYONTTRA® European Royalty

BridgeBio to Host Limb-girdle Muscular Dystrophy Type 2I/R9 Investor Webinar on Friday, July 11th at 8:00 am ET

Jun 26, 2025, 7:30 AM EDT - 10 months ago

BridgeBio to Host Limb-girdle Muscular Dystrophy Type 2I/R9 Investor Webinar on Friday, July 11th at 8:00 am ET

BridgeBio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025

Jun 2, 2025, 7:30 AM EDT - 11 months ago

BridgeBio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025

Acoramidis Reduced Incidence of Atrial Fibrillation Events in Patients with ATTR-CM

May 20, 2025, 7:30 AM EDT - 11 months ago

Acoramidis Reduced Incidence of Atrial Fibrillation Events in Patients with ATTR-CM

Early and Sustained Increase in Serum TTR Levels by Acoramidis Independently Predicted Improved Survival in the ATTRibute-CM Study

May 19, 2025, 12:33 PM EDT - 11 months ago

Early and Sustained Increase in Serum TTR Levels by Acoramidis Independently Predicted Improved Survival in the ATTRibute-CM Study

First Participant Dosed with Acoramidis in ACT-EARLY, the First Ever ATTR Primary Prevention Study

May 13, 2025, 7:30 AM EDT - 1 year ago

First Participant Dosed with Acoramidis in ACT-EARLY, the First Ever ATTR Primary Prevention Study

BridgeBio to Present Clinical Outcomes, Quality of Life Measures and Incidence of Atrial Fibrillation Events in Patients with ATTR-CM from the ATTRibute-CM Study at the Annual Congress of the Heart Failure Association of the ESC

May 12, 2025, 7:30 AM EDT - 1 year ago

BridgeBio to Present Clinical Outcomes, Quality of Life Measures and Incidence of Atrial Fibrillation Events in Patients with ATTR-CM from the ATTRibute-CM Study at the Annual Congress of the Heart Failure Association of the ESC

Nomorelies
Nomorelies Apr. 15 at 12:01 AM
$BBIO Nice!
0 · Reply
Nomorelies
Nomorelies Apr. 14 at 1:39 PM
$BBIO
0 · Reply
MiamiDreamin
MiamiDreamin Apr. 14 at 1:16 AM
$BBIO calls came in today might be news coming
0 · Reply
Alien1980
Alien1980 Apr. 13 at 9:38 PM
$BBIO watch for the close above 78.5 for 79.8 nice chart, similar to $MRVL that put in a new ATH .. nice intraday swing that will be on the continuation WL
0 · Reply
Alien1980
Alien1980 Apr. 13 at 7:47 PM
$BBIO Wowza! Just absolutely ripped. 75-79 👽👽
0 · Reply
theta_cat_purrs
theta_cat_purrs Apr. 13 at 7:31 PM
$BBIO 🟢 BULLISH BBIO — SWEEP: CALL $75 May 15 | Score: 65/100 | $300K IV Rank: n/a | Δ 0.00 | 31 DTE Sweep at ask · Regime: risk_on · 📊 BUY 3 CONTRACTS @ ~$6.45 · Risk: $1935 (1.0% acct) | Max loss: $1935 · Target: +50% → ~$9.67 by 2026-04-16 (3d) · Stop: -35% → cut at ~$4.19
0 · Reply
Quantumup
Quantumup Apr. 10 at 4:18 PM
BofA provided its Takeaways from their Inaugural Doctor's Day event [It's a broad research report: many Tx targets; many tickers] -- On $BBIO (Buy; $95) it said: Achondroplasia: oral is the future $ASND $BMRN $TYRA SNY PFE Here's what else BofA had to say in its note to investors: https://x.com/Quantumup1/status/2042637442155462924?s=20
0 · Reply
Nomorelies
Nomorelies Apr. 10 at 1:14 PM
$BBIO Inflation jitters. Hold!
0 · Reply
topstockalerts
topstockalerts Apr. 9 at 8:32 PM
RBC sees 35% upside ahead for BridgeBio Pharma RBC is bullish on BridgeBio Pharma , initiating coverage on the stock with an outperform rating on Wednesday. While the stock has tripled since the approval of its heart disease drug Attruby in November 2022, the firm believes it has more room to run. Its $100 price target suggests about 35% upside from Wednesday’s close. “Attruby is off to a fantastic start (annualizing ~$600M just a year post approval, and we are seeing a recent ‘second wave’ of acceleration in scripts) and our proprietary survey of 40 cardiologists clearly suggests that we are still in the early innings of uptake,” analyst Luca Issi said in a note to clients. $BBIO
0 · Reply
DonCorleone77
DonCorleone77 Apr. 9 at 6:13 PM
$BBIO Attached is a RBC Capital Markets analyst note regarding BBIO issued today.
1 · Reply
DonCorleone77
DonCorleone77 Apr. 9 at 6:13 PM
$BBIO Attached is a Barclays analyst note regarding BBIO issued today.
0 · Reply
LMXPERTEN
LMXPERTEN Apr. 9 at 6:11 PM
$BBIO the real biotech pros know this is only the beginning!
0 · Reply
Nomorelies
Nomorelies Apr. 9 at 5:10 PM
$BBIO
0 · Reply
jpcalm68
jpcalm68 Apr. 8 at 8:45 PM
$BBIO I'm going to repeat this from time to time. BridgeBio is building a long term juggernaut of a company.
0 · Reply
DonCorleone77
DonCorleone77 Apr. 8 at 8:25 PM
$BBIO BridgeBio initiated with an Outperform at RBC Capital RBC Capital analyst Luca Issi initiated coverage of BridgeBio with an Outperform rating and $100 price target. A survey of 40 cardiologists suggests the Attruby remains in the "early innings of the uptake," the analyst tells investors in a research note. While ongoing tafamidis legal dispute has implications for the durability of the franchise, generic Vyndamax is unlikely to enter the market any time soon, the analyst tells investors in a research note. RBC also believes the rest of BridgeBio's pipeline remains largely underappreciated at current share levels.
0 · Reply
Quantumup
Quantumup Apr. 8 at 4:45 PM
Barclays reiterated Top Idea $BBIO Overweight; $157, and said: We expect continued strength from Attruby launch and we think mgmt sounds upbeat on commercial trends & patient starts. $ALNY $PFE ASND BMRN TYRA SRPT BAYRY Here's what else Barclays had to say: https://x.com/Quantumup1/status/2041919288076861876?s=20
0 · Reply
sampeper
sampeper Apr. 2 at 4:07 PM
$BBIO Mizuho Lifts PT on BridgeBio Pharma (BBIO) to $106 From $91 – Here’s Why https://uk.finance.yahoo.com/news/mizuho-lifts-pt-bridgebio-pharma-150615803.html
0 · Reply
sampeper
sampeper Apr. 2 at 4:05 PM
$BBIO Jefferies reiterates Buy on BridgeBio Pharma stock, $100 target https://www.investing.com/news/analyst-ratings/jefferies-reiterates-buy-on-bridgebio-pharma-stock-100-target-93CH-4588555
0 · Reply
sampeper
sampeper Apr. 2 at 4:03 PM
$BBIO News | Articles | April 1, 2026 Attruby reduces risk of death by 49% in rare heart condition in long-term study https://www.managedhealthcareexecutive.com/view/attruby-reduces-risk-of-death-by-49-in-rare-heart-condition-in-long-term-study
0 · Reply
ChipDistribution7
ChipDistribution7 Apr. 1 at 9:28 AM
Market Pulse: Key Tickers Entering High-Watch Zones Market sentiment is aligning across multiple sectors as several key names show signs of significant momentum. The current watchlist spans electric vehicles, AI compute, biotech, and energy infrastructure: $TSLA, $NVDA, $BBIO, F, and GLNG. As technical setups and fundamental catalysts converge, these tickers are drawing increased attention within their respective industries. With market themes beginning to resonate, it is a crucial time to monitor broader trends and individual company updates.
0 · Reply
resq1
resq1 Mar. 31 at 8:26 PM
$OMER this is the next $BBIO
0 · Reply
LMXPERTEN
LMXPERTEN Mar. 31 at 7:39 PM
$BBIO crushing even with xbi
0 · Reply